argenx SE (NASDAQ:ARGX) Shares Bought by Simplify Asset Management Inc.

Simplify Asset Management Inc. raised its holdings in argenx SE (NASDAQ:ARGX) by 64.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,419 shares of the company’s stock after acquiring an additional 944 shares during the period. Simplify Asset Management Inc.’s holdings in argenx were worth $1,311,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ARGX. Profund Advisors LLC boosted its position in argenx by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after purchasing an additional 28 shares during the period. Wealth Alliance raised its stake in shares of argenx by 4.8% in the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after purchasing an additional 29 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of argenx by 51.3% in the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares in the last quarter. Toronto Dominion Bank raised its stake in shares of argenx by 16.5% in the 1st quarter. Toronto Dominion Bank now owns 303 shares of the company’s stock valued at $119,000 after purchasing an additional 43 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its stake in argenx by 3.1% during the second quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock worth $737,000 after acquiring an additional 52 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Trading Down 4.3 %

NASDAQ:ARGX traded down $25.87 during trading hours on Friday, reaching $569.17. 175,393 shares of the company’s stock were exchanged, compared to its average volume of 307,122. argenx SE has a 12 month low of $327.73 and a 12 month high of $611.22. The business’s 50-day simple moving average is $552.45 and its two-hundred day simple moving average is $479.91.

argenx (NASDAQ:ARGX) last issued its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. The firm had revenue of $588.88 million during the quarter, compared to analysts’ expectations of $543.29 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. During the same period last year, the firm posted ($1.25) earnings per share. On average, research analysts anticipate that argenx SE will post 2.2 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ARGX. Guggenheim increased their price objective on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. JPMorgan Chase & Co. increased their price objective on shares of argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research note on Monday, November 4th. Raymond James restated a “strong-buy” rating and issued a $605.00 price target on shares of argenx in a research note on Thursday, October 10th. Scotiabank upgraded shares of argenx from a “sector perform” rating to a “sector outperform” rating and raised their price target for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Finally, Barclays upgraded shares of argenx from an “equal weight” rating to an “overweight” rating in a research note on Tuesday, August 6th. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, argenx has an average rating of “Moderate Buy” and an average price target of $619.79.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.